🚨 Deep dive into RMD Open RA prevention review 👆🏽
1Risk Stratification 📊: RA incidence 0.04% (general), 0.2% (FDRs), 15-42% (ACPA with arthralgia). Two-year RA risk: 57% (ACPA /RF ), 31% (ACPA alone).
#RiskProfiling
2Autoantibody Dynamics 🩺: ACPA precedes RA by years; high titers RF predict faster onset. IgA ACPA linked to mucosal triggers.
#Biomarkers
3Mucosal Triggers 🦠: P. gingivalis (oral), smoking (lung), and gut dysbiosis drive RA. Prevotella-rich gut in pre-RA; SCFAs (butyrate) may suppress inflammation.
#Microbiome
4Lung Pathology 🫁: 76% of ACPA show HRCT airway changes. Sputum NETs, neutrophil extracellular traps, signal pre-RA lung inflammation.
#Pulmonary
5Immune Dysregulation 🧬: HLA-DRB1*04:01-restricted CD4 /CD8 T-cells target citrullinated antigens pre-RA. B-cell hyperactivity amplifies autoimmunity.
#TCell
6Prevention Trials 🧪: Methotrexate, rituximab, abatacept delay RA but don’t prevent long-term. PRAIRI trial: rituximab delays onset by 12 months.
#DMARDs
7Lifestyle Impact 💪: Smoking cessation cuts RA risk by 30%. High-fiber diet, oral hygiene reduce mucosal inflammation. Omega-3 may lower ACPA levels.
#Prevention
8Emerging Therapies 🔬: CAR-Tregs, antigen-specific tolerization, and B-cell depletion (e.g., obinutuzumab) aim to reset immunity. Gut-targeted probiotics under trial.
#Immunotherapy
9Seronegative RA ❓: Citrullination, carbamylation spark autoimmunity sans ACPA/RF. Limited data; needs proteomic focus.
#Seronegative
10Biomarker Gaps 🧩: Synovial biopsies show inflammation pre-RA; no standardized predictive panel yet. Multi-omics (proteomics, metabolomics) key for precision.
#Diagnostics
🔗 DOI: 10.1136/rmdopen-2025-000378
#RheumatoidArthritis #PreRA #Autoimmunity #PrecisionMedicine
Share to amplify RA prevention science! 🌍